Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 21-30 of 101 for soft tissue sarcoma

Edit search filters
  1. A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

    Jacksonville, FL, Rochester, MN

  2. Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma

    Jacksonville, FL

  3. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

    Jacksonville, FL, Rochester, MN

  4. A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma

    Jacksonville, FL

  5. Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

    Jacksonville, FL, Rochester, MN

  6. A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A Study to Evaluate Trabectedin with Olaparib in Advanced Unresectable or Metastatic Sarcoma

    Rochester, MN

  9. Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

    Rochester, MN

  10. Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

    Scottsdale/Phoenix, AZ, Jacksonville, FL

.

Mayo Clinic Footer